Literature DB >> 34596839

Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy.

Hee Seung Seo1,2, Chi-Pin James Wang1, Wooram Park3, Chun Gwon Park4,5,6,7.   

Abstract

Cancer immunotherapy has become the new paradigm of cancer treatment. The introduction and discovery of various therapeutic agents have also accelerated the application of immunotherapy in clinical trials. However, despite the significant potency and demonstrated advantages of cancer immunotherapy, its clinical application to patients faces several safety and efficacy issues, including autoimmune reactions, cytokine release syndrome, and vascular leak syndrome-related issues. In addressing these problems, biomaterials traditionally used for tissue engineering and drug delivery are attracting attention. Among them, hydrogels can be easily injected into tumors with drugs, and they can minimize side effects by retaining immune therapeutics at the tumor site for a long time. This article reviews the status of functional hydrogels for effective cancer immunotherapy. First, we describe the basic mechanisms of cancer immunotherapy and the advantages of using hydrogels to apply these mechanisms. Next, we summarize recent advances in the development of functional hydrogels designed to locally release various immunotherapeutic agents, including cytokines, cancer immune vaccines, immune checkpoint inhibitors, and chimeric antigen receptor-T cells. Finally, we briefly discuss the current problems and possible prospects of hydrogels for effective cancer immunotherapy.
© 2021. The Korean Tissue Engineering and Regenerative Medicine Society.

Entities:  

Keywords:  Biomaterials; Cancer immunotherapy; Drug delivery systems; Hydrogels; Vaccine

Mesh:

Substances:

Year:  2021        PMID: 34596839      PMCID: PMC8971265          DOI: 10.1007/s13770-021-00369-6

Source DB:  PubMed          Journal:  Tissue Eng Regen Med        ISSN: 1738-2696            Impact factor:   4.451


  146 in total

1.  STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.

Authors:  Juan Fu; David B Kanne; Meredith Leong; Laura Hix Glickman; Sarah M McWhirter; Edward Lemmens; Ken Mechette; Justin J Leong; Peter Lauer; Weiqun Liu; Kelsey E Sivick; Qi Zeng; Kevin C Soares; Lei Zheng; Daniel A Portnoy; Joshua J Woodward; Drew M Pardoll; Thomas W Dubensky; Young Kim
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

2.  Supramolecular polymeric hydrogels.

Authors:  Eric A Appel; Jesús del Barrio; Xian Jun Loh; Oren A Scherman
Journal:  Chem Soc Rev       Date:  2012-08-13       Impact factor: 54.564

Review 3.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

Review 4.  Cytokines and the inception of CD8 T cell responses.

Authors:  Maureen A Cox; Laurie E Harrington; Allan J Zajac
Journal:  Trends Immunol       Date:  2011-03-02       Impact factor: 16.687

5.  In Situ Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy.

Authors:  Yue Yin; Xiaoyang Li; Haixia Ma; Jie Zhang; Di Yu; Ruifang Zhao; Shengji Yu; Guangjun Nie; Hai Wang
Journal:  Nano Lett       Date:  2021-02-17       Impact factor: 11.189

6.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

Authors:  Donald M O'Rourke; MacLean P Nasrallah; Arati Desai; Jan J Melenhorst; Keith Mansfield; Jennifer J D Morrissette; Maria Martinez-Lage; Steven Brem; Eileen Maloney; Angela Shen; Randi Isaacs; Suyash Mohan; Gabriela Plesa; Simon F Lacey; Jean-Marc Navenot; Zhaohui Zheng; Bruce L Levine; Hideho Okada; Carl H June; Jennifer L Brogdon; Marcela V Maus
Journal:  Sci Transl Med       Date:  2017-07-19       Impact factor: 17.956

7.  IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation.

Authors:  Shlomo Z Ben-Sasson; Jane Hu-Li; Juan Quiel; Stephane Cauchetaux; Maya Ratner; Ilana Shapira; Charles A Dinarello; William E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

8.  Supramolecular nanostructures formed by anticancer drug assembly.

Authors:  Andrew G Cheetham; Pengcheng Zhang; Yi-an Lin; Lye Lin Lock; Honggang Cui
Journal:  J Am Chem Soc       Date:  2013-02-13       Impact factor: 15.419

9.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

10.  In Situ Gelling Hydrogel with Anti-Bacterial Activity and Bone Healing Property for Treatment of Osteomyelitis.

Authors:  Sun Woo Jung; Se Heang Oh; In Soo Lee; June-Ho Byun; Jin Ho Lee
Journal:  Tissue Eng Regen Med       Date:  2019-08-22       Impact factor: 4.169

View more
  2 in total

1.  Nano-sized Materials for Tissue Regeneration and Immune/Cancer Therapy.

Authors:  Suk Ho Bhang; Inho Jo
Journal:  Tissue Eng Regen Med       Date:  2022-04       Impact factor: 4.169

Review 2.  Novel Trends in Hydrogel Development for Biomedical Applications: A Review.

Authors:  Pablo Sánchez-Cid; Mercedes Jiménez-Rosado; Alberto Romero; Víctor Pérez-Puyana
Journal:  Polymers (Basel)       Date:  2022-07-26       Impact factor: 4.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.